VCAP-AMP-VECP regimen: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} ==Overview== {{PAGENAME}} refers to a regimen consisting of with vincristine, cyclophosphamide, doxorubicin|doxorubicin (ad..." |
No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of with [[vincristine]], [[cyclophosphamide]], [[doxorubicin|doxorubicin (adriamycin)]], and [[prednisone]] (VCAP), [[doxorubicin|doxorubicin (adriamycin)]], [[MCNU|ranimustine]], and [[prednisone]] (AMP), and [[vindesine]], [[etoposide]], [[carboplatin]], and [[prednisone]] (VECP) used to treat [[human T-lymphotropic virus]] type I-associated [[Adult T-cell leukemia/lymphoma|adult T-cell leukemia-lymphoma]] (ATLL)<ref name="pmid17968021">{{cite journal| author=Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y et al.| title=VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. | journal=J Clin Oncol | year= 2007 | volume= 25 | issue= 34 | pages= 5458-64 | pmid=17968021 | doi=10.1200/JCO.2007.11.9958 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17968021 }} </ref> | {{PAGENAME}} refers to a regimen consisting of with [[vincristine]], [[cyclophosphamide]], [[doxorubicin|doxorubicin (adriamycin)]], and [[prednisone]] (VCAP), [[doxorubicin|doxorubicin (adriamycin)]], [[MCNU|ranimustine]], and [[prednisone]] (AMP), and [[vindesine]], [[etoposide]], [[carboplatin]], and [[prednisone]] (VECP) used to treat [[human T-lymphotropic virus]] type I-associated [[Adult T-cell leukemia/lymphoma|adult T-cell leukemia-lymphoma]] (ATLL)<ref name="pmid17968021">{{cite journal| author=Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y et al.| title=VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. | journal=J Clin Oncol | year= 2007 | volume= 25 | issue= 34 | pages= 5458-64 | pmid=17968021 | doi=10.1200/JCO.2007.11.9958 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17968021 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|V|Vincristine}} | {{chemo|V|Vincristine}} | ||
{{chemo|C|Cyclophosphamide}} | {{chemo|C|Cyclophosphamide}} | ||
{{chemo|A|Doxorubicin (Adriamycin)}} | {{chemo|A|Doxorubicin (Adriamycin)}} | ||
{{chemo|P|Prednisone} | |||
{{chemo|P|Prednisone}} | |||
{{chemo|A|Doxorubicin (Adriamycin)}} | {{chemo|A|Doxorubicin (Adriamycin)}} | ||
| Line 27: | Line 28: | ||
{{chemo|P|Prednisone}} | {{chemo|P|Prednisone}} | ||
==Indications== | ==Indications== | ||
* [[Human T-lymphotropic virus]] type I-associated [[Adult T-cell leukemia/lymphoma|Adult T-cell leukemia-lymphoma]] (ATLL)<ref name="pmid17968021">{{cite journal| author=Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y et al.| title=VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. | journal=J Clin Oncol | year= 2007 | volume= 25 | issue= 34 | pages= 5458-64 | pmid=17968021 | doi=10.1200/JCO.2007.11.9958 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17968021 }} </ref> | * [[Human T-lymphotropic virus]] type I-associated [[Adult T-cell leukemia/lymphoma|Adult T-cell leukemia-lymphoma]] (ATLL)<ref name="pmid17968021">{{cite journal| author=Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y et al.| title=VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. | journal=J Clin Oncol | year= 2007 | volume= 25 | issue= 34 | pages= 5458-64 | pmid=17968021 | doi=10.1200/JCO.2007.11.9958 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17968021 }} </ref> | ||
Latest revision as of 14:11, 30 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
VCAP-AMP-VECP regimen refers to a regimen consisting of with vincristine, cyclophosphamide, doxorubicin (adriamycin), and prednisone (VCAP), doxorubicin (adriamycin), ranimustine, and prednisone (AMP), and vindesine, etoposide, carboplatin, and prednisone (VECP) used to treat human T-lymphotropic virus type I-associated adult T-cell leukemia-lymphoma (ATLL)[1]
Regimen
VVincristine
CCyclophosphamide
ADoxorubicin (Adriamycin)
PPrednisone
ADoxorubicin (Adriamycin)
MRanimustine (MCNU)
PPrednisone
VVindesine
EEtoposide
CCarboplatin
PPrednisone
Indications
- Human T-lymphotropic virus type I-associated Adult T-cell leukemia-lymphoma (ATLL)[1]
References
- ↑ 1.0 1.1 Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y; et al. (2007). "VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801". J Clin Oncol. 25 (34): 5458–64. doi:10.1200/JCO.2007.11.9958. PMID 17968021.